1stOncology™: Cancer Intelligence Service – Page 17211 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

AskAt Inc. Launch

On February 1, 2013 AskAt reported that it began business operations (Press release, AskAt, FEB 1, 2013, View Source [SID1234535067]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

AskAt was launched as an independent company from RaQualia Pharma Inc. to focus on developing several strategic programs, including EP4 receptor antagonists, cyclooxygenase (COX-2) inhibitor, and serotonin 5-HT4 partial agonist. AskAt will also work on new projects.

AskAt will seek to implement innovative structures and collaboration-centric platforms to develop these programs, maximize their value, and then license them to pharmaceutical companies worldwide. Part of this process optimization will include partnerships with academia, public funding, as well as private financing on a program-specific basis.

Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL

On February 1, 2013 Seattle Genetics reported that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications: (1) the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen (Press release Seattle Genetics, FEB 1, 2013, View Source;p=irol-newsArticle&ID=1780634&highlight= [SID:1234500570]). The indications for ADCETRIS were authorized based on promising response rates demonstrated in single-arm trials. No data demonstrate increased survival with ADCETRIS.

(Filing, 10-Q, Champions Oncology, JAN 31, 2013, View Source [SID:1234504159])

Teva Announces Termination of Agreements with CureTech

On January 31, 2013 Teva reported the termination of its collaboration with CureTech Ltd (Press release Teva, JAN 31, 2013, View Source;p=irol-newsArticle&ID=1779781 [SID:1234500813]).

"We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients," stated Dr. Michael Hayden, President and CEO of R&D and Chief R&D Officer.

CT-011 is a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. CT-011 was assessed in several phase I and II clinical studies in various cancer indications including diffuse large B-cell lymphoma (DLBCL), colon cancer, metastatic melanoma and additional investigator initiated studies.

Teva entered into agreements with CureTech in 2006. Teva intends to book a noncash net charge of $109 million as a result of the impairment of its investment in CureTech.

(Filing 10-Q , Lion Biotechnologies, JAN 25, 2013, View Source [SID:1234501579])